UK Clears 25 mg Daily Wegovy Pill; 30M Americans Now on GLP-1s
GLP•MHRA approved 25 mg once-daily semaglutide tablets for adults with BMI ≥30 kg/m2 or ≥27 kg/m2 plus a weight-related condition, with private UK prescriptions launching within weeks. About 30 million US adults use GLP-1 drugs, cutting fast-food addressable market by 27–30%, while some employers plan to drop obesity-drug coverage in 2027.
1. Company Gains UK Oral GLP-1 Approval
MHRA has approved semaglutide 25 mg once-daily tablets for adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) plus a weight-related condition. Novo Nordisk expects private prescriptions to begin within weeks as an alternative to weekly injections alongside diet and exercise.
2. Rising US Adoption Hits Fast-Food Demand
Approximately 30 million US adults now use GLP-1 therapies for weight management, reducing the fast-food addressable market by an estimated 27–30%. This shift poses a sales challenge for quick-service restaurants facing a significant drop in calorie-seeking consumers.
3. Employers to Cut GLP-1 Coverage in 2027
Several large US employers plan to drop coverage of GLP-1 obesity drugs in 2027 despite growing usage and lower prices from major manufacturers. The move could slow patient uptake and pressure drugmakers’ pricing and revenue forecasts.
